Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays

Journal of Molecular Diagnostics

Volumn 19, Issue 1, 2017, Pages 43-56

  Kadri, Sabah ^a   Long, Bradley C ^a   Mujacic, Ibro ^a   Zhen, Chao J ^a   Wurst, Michelle N ^a   Sharma, Shruti ^a   McDonald, Nadia ^a   Niu, Nifang ^a   Benhamed, Sonia ^a   Tuteja, Jigyasa H ^b   Seiwert, Tanguy Y ^a   White, Kevin P ^b   McNerney, Megan E ^a   Fitzpatrick, Carrie ^a   Wang, Y Lynn ^a   Furtado, Larissa V ^a   Segal, Jeremy P ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABL1 PROTEIN; ANAPLASTIC LYMPHOMA KINASE; ASXL1 PROTEIN; ATRX PROTEIN; B RAF KINASE; BCOR PROTEIN; BCORL1 PROTEIN; CALR PROTEIN; CBL PROTEIN; CBLB PROTEIN; CBLC PROTEIN; CSF3R PROTEIN; CUX1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA METHYLTRANSFERASE 3A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLT3 LIGAND; K RAS PROTEIN; PROTEIN; PROTEIN P53; PROTEIN RET; ROS1 PROTEIN; SCATTER FACTOR RECEPTOR; SMAD4 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR GATA 2; UNCLASSIFIED DRUG; VASCULOTROPIN;

AMPLICON; AMPLICON SEQUENCING ASSAY; BENCHMARKING; CONFERENCE PAPER; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE DUPLICATION; GENE FUSION; GENETIC ANALYSIS; GENOME ANALYSIS; HEMATOLOGIC MALIGNANCY; HUMAN; INDEL MUTATION; NEXT GENERATION SEQUENCING; ONCOLOGY; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; VALIDATION PROCESS; DNA MUTATIONAL ANALYSIS; GENE FREQUENCY; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; LIMIT OF DETECTION; MUTATION; NEOPLASM; STANDARD; STANDARDS; TUMOR GENE; VALIDATION STUDY;

BENCHMARKING; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; GENE FREQUENCY; GENE FUSION; GENES, NEOPLASM; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LIMIT OF DETECTION; MUTATION; NEOPLASMS; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY;

EID: 85006476238     PISSN: 15251578     EISSN: 19437811     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2016.07.012     Document Type: Article

References (29)

1. 1 Frampton, G.M., Fichtenholtz, A., Otto, G.A., Wang, K., Downing, S.R., He, J., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31 (2013), 1023–1031.
2. 2 Cottrell, C.E., Al-Kateb, H., Bredemeyer, A.J., Duncavage, E.J., Spencer, D.H., Abel, H.J., Lockwood, C.M., Hagemann, I.S., O'Guin, S.M., Burcea, L.C., Validation of a next-generation sequencing assay for clinical molecular oncology. J Mol Diagn 16 (2014), 89–105.
3. 3 Pritchard, C.C., Salipante, S.J., Koehler, K., Smith, C., Scroggins, S., Wood, B., Wu, D., Lee, M.K., Dintzis, S., Adey, A., Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn 16 (2014), 56–67.
4. 4 Tsongalis, G.J., Peterson, J.D., De, A., Tunkey, C.D., Gallagher, T.L., Strausbaugh, L.D., Wells, W.A., Amos, C.I., Routine use of the Ion Torrent AmpliSeq™ Cancer Hotspot Panel for identification of clinically actionable somatic mutations. Clin Chem Lab Med 52 (2014), 707–714.
5. 5 Cheng, D.T., Mitchell, T.N., Zehir, A., Shah, R.H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z.Y., Won, H.H., Scott, S.N., Brannon, A.R., O'Reilly, C., Sadowska, J., Casanova, J., Yannes, A., Hechtman, J.F., Yao, J., Song, W., Ross, D.S., Oultache, A., Dogan, S., Borsu, L., Hameed, M., Nafa, K., Arcila, M.E., Ladanyi, M., Berger, M.F., Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 17 (2015), 251–264.
6. 6 de Leng, W.W., Gadellaa-van Hooijdonk, C.G., Barendregt-Smouter, F.A., Koudijs, M.J., Nijman, I., Hinrichs, J.W.J., Cuppen, E., van Lieshout, S., Loberg, R.D., de Jonge, M., Voest, E.E., de Weger, R.A., Steeghs, N., Langenberg, M.H.G., Sleijfer, S., Willems, S.M., Lolkema, M.P., Targeted next generation sequencing as a reliable diagnostic assay for the detection of somatic mutations in tumours using minimal DNA amounts from formalin fixed paraffin embedded material. PLoS One, 11, 2016, e0149405.
7. 7 Fisher, K.E., Zhang, L., Wang, J., Smith, G.H., Newman, S., Schneider, T.M., Pillai, R.N., Kudchadkar, R.R., Owonikoko, T.K., Ramalingam, S.S., Lawson, D.H., Delman, K.A., El-Rayes, B.F., Wilson, M.M., Sullivan, H.C., Morrison, A.S., Balci, S., Adsay, N.V., Gal, A.A., Sica, G.L., Saxe, D.F., Mann, K.P., Hill, C.E., Khuri, F.R., Rossi, M.R., Clinical validation and implementation of a targeted next-generation sequencing assay to detect somatic variants in non-small cell lung, melanoma, and gastrointestinal malignancies. J Mol Diagn 18 (2016), 299–315.
8. 8 Daber, R., Sukhadia, S., Morrissette, J.J., Understanding the limitations of next generation sequencing informatics, an approach to clinical pipeline validation using artificial data sets. Cancer Genet 206 (2013), 441–448.
9. 9 Bennett, N.C., Farah, C.S., Next-generation sequencing in clinical oncology: next steps towards clinical validation. Cancers (Basel) 6 (2014), 2296–2312.
10. 10 Torsvik, A., Stieber, D., Enger, P.Ø., Golebiewska, A., Molven, A., Svendsen, A., Westermark, B., Niclou, S.P., Olsen, T.K., Chekenya Enger, M., Bjerkvig, R., U-251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells. Cancer Med 3 (2014), 812–824.
11. 11 Hughes, P., Marshall, D., Reid, Y., Parkes, H., Gelber, C., The costs of using unauthenticated, over-passaged cell lines: how much more data do we need?. Biotechniques, 43, 2007, 575 577–578, 581–582 passim.
12. 12 Samorodnitsky, E., Jewell, B.M., Hagopian, R., Miya, J., Wing, M.R., Lyon, E., Damodaran, S., Bhatt, D., Reeser, J.W., Datta, J., Evaluation of hybridization capture versus amplicon-based methods for whole-exome sequencing. Hum Mutat 36 (2015), 903–914.
13. 13 Sie, D., Snijders, P.J.F., Meijer, G.A., Doeleman, M.W., van Moorsel, M.I.H., van Essen, H.F., Eijk, P.P., Grünberg, K., van Grieken, N.C.T., Thunnissen, E., Verheul, H.M., Smit, E.F., Ylstra, B., Heideman, D.A.M., Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. Cell Oncol (Dordr) 37 (2014), 353–361.
14. 14 Simen, B.B., Yin, L., Goswami, C.P., Davis, K.O., Bajaj, R., Gong, J.Z., Peiper, S.C., Johnson, E.S., Wang, Z.X., Validation of a next-generation-sequencing cancer panel for use in the clinical laboratory. Arch Pathol Lab Med 139 (2015), 508–517.
15. 15 Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., The Sequence Alignment/Map format and SAMtools. Bioinformatics 25 (2009), 2078–2079.
16. 16 Kadri, S., Zhen, C.J., Wurst, M.N., Long, B.C., Jiang, Z.F., Wang, Y.L., Furtado, L.V., Segal, J.P., Amplicon indel hunter is a novel bioinformatics tool to detect large somatic insertion/deletion mutations in amplicon-based next-generation sequencing data. J Mol Diagn 17 (2015), 635–643.
17. 17 Bolger, A.M., Lohse, M., Usadel, B., Trimmomatic: a flexible trimmer for Illumina Sequence Data. Bioinformatics 30 (2014), 2114–2120.
18. 18 Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. ArXiv Prepr 2013, [Epub ahead of print] doi: arXiv:1303.3997v2.
19. 19 Mose, L.E., Wilkerson, M.D., Hayes, D.N., Perou, C.M., Parker, J.S., ABRA: improved coding indel detection via assembly-based realignment. Bioinformatics 30 (2014), 2813–2815.
20. 20 Ye, K., Schulz, M.H., Long, Q., Apweiler, R., Ning, Z., Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25 (2009), 2865–2871.
21. 21 McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20 (2010), 1297–1303.
22. 22 Abu-Duhier, F.M., Goodeve, A.C., Wilson, G.A., Care, R.S., Peake, I.R., Reilly, J.T., Genomic structure of human FLT3: implications for mutational analysis. Br J Haematol 113 (2001), 1076–1077.
23. 23 Zook, J.M., Chapman, B., Wang, J., Mittelman, D., Hofmann, O., Hide, W., Salit, M., Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls. Nat Biotechnol 32 (2014), 246–251.
24. 24 Ye, K., Wang, J., Jayasinghe, R., Lameijer, E.W., McMichael, J.F., Ning, J., McLellan, M.D., Xie, M., Cao, S., Yellapantula, V., Huang, K.L., Scott, A., Foltz, S., Niu, B., Johnson, K.J., Moed, M., Slagboom, P.E., Chen, F., Wendl, M.C., Ding, L., Systematic discovery of complex insertions and deletions in human cancers. Nat Med 22 (2016), 97–104.
25. 25 1000 Genomes Project Consortium, Abecasis, G.R., Auton, A., Brooks, L.D., DePristo, M.A., Durbin, R.M., Handsaker, R.E., Kang, H.M., Marth, G.T., McVean, G.A., An integrated map of genetic variation from 1,092 human genomes. Nature 491 (2012), 56–65.
26. 26 Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T., Misawa, S., Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10 (1996), 1911–1918.
27. 27 Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, S.E., Belton, A.A., Walker, H., Wheatley, K., Bowen, D.T., Burnett, A.K., Goldstone, A.H., Linch, D.C., The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98 (2001), 1752–1759.
28. 28 Smith, C.C., Wang, Q., Chin, C.-S., Salerno, S., Damon, L.E., Levis, M.J., Perl, A.E., Travers, K.J., Wang, S., Hunt, J.P., Zarrinkar, P.P., Schadt, E.E., Kasarskis, A., Kuriyan, J., Shah, N.P., Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485 (2012), 260–263.
29. 29 Robinson, J.T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E.S., Getz, G., Mesirov, J.P., Integrative genomics viewer. Nat Biotechnol 29 (2011), 24–26.